# Contents

## EDITORIAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1384</td>
<td>Remission of type 2 diabetes mellitus</td>
<td>Nakhleh A, Halfin E, Shehadeh N</td>
</tr>
<tr>
<td>1390</td>
<td>Diabetes remission and nonalcoholic fatty pancreas disease</td>
<td>Wu WJ</td>
</tr>
<tr>
<td>1394</td>
<td>Management of gestational diabetes mellitus via nutritional interventions: The relevance of gastric emptying</td>
<td>Huang WK, Jalleh RJ, Rayner CK, Wu TZ</td>
</tr>
<tr>
<td>1404</td>
<td>Adiposity in Chinese people with type 1 diabetes</td>
<td>Wu NW, Lyu XF, An ZM, Li SY</td>
</tr>
<tr>
<td>1409</td>
<td>Diabetes and tuberculosis: An emerging dual threat to healthcare</td>
<td>Shetty S, Pappachan JM, Fernandez CJ</td>
</tr>
</tbody>
</table>

## REVIEW

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1417</td>
<td>Patient-centered care in diabetes care-concepts, relationships and practice</td>
<td>Chen TT, Su WC, Liu MI</td>
</tr>
<tr>
<td>1430</td>
<td>Insulin resistance as the molecular link between diabetes and Alzheimer's disease</td>
<td>Abdalla MMI</td>
</tr>
</tbody>
</table>

## MINIREVIEWS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1461</td>
<td>Update on evidence-based clinical application of sodium-glucose cotransporter inhibitors: Insight to uncommon cardiovascular disease scenarios in diabetes</td>
<td>Tao SB, Lu X, Ye ZW, Tong NW</td>
</tr>
</tbody>
</table>
## Contents

**World Journal of Diabetes**  
Monthly Volume 15 Number 7 July 15, 2024

### ORIGINAL ARTICLE

**Retrospective Cohort Study**

1477  
Association between glucose levels of children with type 1 diabetes and parental economic status in mobile health application  

**Retrospective Study**

1489  
Association between glucose-lowering drugs and circulating insulin antibodies induced by insulin therapy in patients with type 2 diabetes  
*Zhang P, Jiang Q, Ding B, Yan RN, Hu Y, Ma JH*

1499  
Clinical efficacy of endovascular revascularization combined with vacuum-assisted closure for the treatment of diabetic foot  
*Lei FR, Shen XF, Zhang C, Li XQ, Zhuang H, Sang HF*

1509  
Magnetic resonance imaging combined with serum endolipin and galactagoglobin-3 to diagnose cerebral infarction in the elderly with diabetes mellitus  
*Zhang YH, Liang D*

1518  
Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety  
*Yu PL, Yu Y, Li S, Mu BC, Nan MH, Pang M*

### Observational Study

1531  
Cut-off value of glycated hemoglobin A1c for detecting diabetic retinopathy in the Chinese population  
*Wen Y, Wang Q*

1537  
Glymphatic function and its influencing factors in different glucose metabolism states  

### Clinical and Translational Research

1551  
Does type 1 diabetes serve as a protective factor against inflammatory bowel disease: A Mendelian randomization study  
*Tong KK, Yu YF, Yang XY, Wu JY, Yu R, Tan CC*

1562  
Network pharmacology and molecular dynamics study of the effect of the *Astragalus-Coptis* drug pair on diabetic kidney disease  
*Zhang MY, Zheng SQ*

### Basic Study

1589  
Interactions between myoblasts and macrophages under high glucose milieus result in inflammatory response and impaired insulin sensitivity  
*Luo W, Zhou Y, Wang LY, Ai L*
SYSTEMATIC REVIEWS
1603 Natural product-based treatment potential for type 2 diabetes mellitus and cardiovascular disease
Shrivastav D, Kumbhakar SK, Srivastava S, Singh DD

META-ANALYSIS
1615 Evaluation of teplizumab's efficacy and safety in treatment of type 1 diabetes mellitus: A systematic review and meta-analysis
Ma XL, Ge D, Hu XJ

SCIENTOMETRICS
1627 Global trends in publications regarding macrophages-related diabetic foot ulcers in the last two decades
Wen JP, Ou SJ, Liu JB, Zhang W, Qu YD, Li JX, Xia CL, Yang Y, Qi Y, Xu CP

LETTER TO THE EDITOR
1645 Atrial fibrillation and prediabetes: A liaison that merits attention!
Batta A, Hatwal J
1648 Serum tumor markers: Can they clinically implicate in type 2 diabetes mellitus?
Reddy KS, Pandiaraj IP, Gaur A, Varatharajan S
1651 Bidirectional link between periodontitis and systemic inflammation in diabetic retinopathy
Nishant P, Sinha S, Sinha RK, Morya AK
ABOUT COVER
Peer Review of World Journal of Diabetes, Erkan Gokce, MD, Professor, Department of Radiology, Tokat Gaziosmanpasa University, School of Medicine, Tokat 60100, Türkiye. drerkgokce@gmail.com

AIMS AND SCOPE
The primary aim of World Journal of Diabetes (WJD, World J Diabetes) is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJD mainly publishes articles reporting research results and findings obtained in the field of diabetes and covering a wide range of topics including risk factors for diabetes, diabetes complications, experimental diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, diabetic angiopathies, diabetic cardiomyopathies, diabetic coma, diabetic ketoacidosis, diabetic nephropathies, diabetic neuropathies, Donohue syndrome, fetal macrosomia, and prediabetic state.

INDEXING/ABSTRACTING
The WJD is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 Edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for WJD as 4.2; JIF without journal self cites: 4.1; 5-year JIF: 4.2; JIF Rank: 40/186 in endocrinology and metabolism; JIF Quartile: Q1; and 5-year JIF Quartile: Q2.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yu-Xi Chen; Production Department Director: Xu Guo; Cover Editor: Jia-Ru Fan.

NAME OF JOURNAL
World Journal of Diabetes

ISSN
ISSN 1948-9358 (online)

LAUNCH DATE
June 15, 2010

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Lu Cai, Md. Shahidul Islam, Michael Horowitz

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
July 15, 2024

COPYRIGHT
© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: office@baishideng.com  https://www.wjgnet.com
Editorial

MicroRNA-630: A promising avenue for alleviating inflammation in diabetic kidney disease

Javier Donate-Correa, Ainhoa González-Luis, Jésica Díaz-Vera, Juan Ramón Hernandez-Fernaud

Specialty type: Endocrinology and metabolism

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peering report’s classification
Scientific Quality: Grade B, Grade C, Grade C
Novelty: Grade B, Grade B, Grade C
Creativity or Innovation: Grade B, Grade B, Grade B
Scientific Significance: Grade B, Grade B, Grade B

Abstract

Diabetic kidney disease (DKD) is one of the complications of diabetes, affecting millions of people worldwide. The relentless progression of this condition can lead to kidney failure, requiring life-altering interventions such as dialysis or transplants. Accumulating evidence suggests that immunologic and inflammatory elements play an important role in initiating and perpetuating the damage inflicted on renal tissues, exacerbating the decline in organ function. Toll-like receptors (TLRs) are a family of receptors that play a role in the activation of the innate immune system by the recognition of pathogen-associated molecular patterns. Recent data from in vitro and in vivo studies have highlighted the critical role of TLRs, mainly TLR2 and TLR4, in the pathogenesis of DKD. In the diabetic milieu, these TLRs recognize diabetic-associated molecular signals, triggering a proinflammatory cascade that initiates and perpetuates inflammation and fibrogenesis in the diabetic kidney. Emerging non-traditional strategies targeting TLR signaling with potential therapeutic implications in DKD have been proposed. One of these approaches is the use of microRNAs, small non-coding RNAs that can regulate gene expression. This editorial comments on the results of this approach carried out in a rat model of diabetes by Wu et al, published in this issue of the World Journal of Diabetes. The results of the experimental study by Wu et al shows that microRNA-630 decreased levels compared to non-diabetic rats. Additionally, microRNA-630 exerted anti-inflammatory effects in the kidneys of diabetic rats through the modulation of TLR4. These findings indicate that the microRNA-630/TLR4 axis might represent a pathological mechanism of DKD and a potential therapeutic target capable of curbing the destructive inflammation characteristic of DKD.

Key Words: Diabetes; Diabetic kidney disease; Inflammation; Toll-like receptor 4;
microRNA-630

Core Tip: Targeting Toll-like receptors (TLRs) via microRNAs is a promising therapeutic approach for reducing inflammation and slowing the progression of diabetic kidney disease (DKD). Understanding how TLR4 expression and signaling are linked to microRNAs regulation, may pave the path for future targeted clinical interventions in DKD.

INTRODUCTION

Diabetic kidney disease (DKD) is a common complication of diabetes and the leading cause of kidney failure worldwide. The enormous incidence of DKD has motivated the study of this complication in the most recent phase-3 randomized clinical trials testing kidney protection. As a result of these trials, two new renal protective drugs have been introduced into clinical practice for the treatment of chronic kidney disease (CKD) in subjects with and without diabetes[1]: Sodium-glucose cotransporter-2 inhibitors and the non-steroidal mineralocorticoid receptor antagonist finerenone[1,2]. However, novel therapies are needed as the residual risk of progression to end-stage renal disease remains in this population.

Inflammation is prevalent in diabetes, contributing to the onset and progression of DKD[3,4]. In this disease, a myriad of factors, including hyperglycemia, advanced glycation end products, lipid accumulation, lipotoxicity and increased urinary albumin excretion, act on renal cells, activating cellular and molecular mechanisms that lead to sustained kidney inflammation. In addition, immune cells are recruited into the renal tissue and contributing to kidney damage[5]. To date, promising clinical trials designed to evaluate effective renoprotection by anti-inflammatory drugs in patients with diabetes have failed or were prematurely stopped due to safety concerns[6-9].

There is striking compelling evidence about the participation of the nuclear factor-kappa B (NF-κB) pathway in the progression of DKD by triggering kidney inflammation and fibrosis[10]. NF-κB is a family of transcription factors involved in different processes, including immune response modulation, cell differentiation and development, inflammation, and tumorigenesis. NF-κB transcription factors are present in cells in an inactive state, forming a complex with inhibitors of NF-κB[10]. Activated NF-κB leads to an increase in the transcription of pro-inflammatory cytokines and chemokines, such as interleukins interleukin-6 (IL-6), IL-1β, and monocyte chemotactic protein-1, thereby initiating local inflammation and leukocyte accumulation[11,12] (Figure 1). The canonical NF-κB pathway responds to diverse stimuli including pathogens which are sensed through multiple classes of pattern-recognition receptors (PRRs) in innate immune cells such as macrophages. Among the cell surface PRRs, Toll-Like receptors (TLRs) have been the most extensively studied. TLRs are a conserved family of pattern recognition receptors that activate downstream inflammatory signaling pathways in response to exogenous microbial pathogens[12], playing a crucial role in the innate immune system. The interplay between TLR4 and NF-κB is a finely tuned mechanism that helps the immune system respond to microbial threats while maintaining balance to prevent excessive inflammation. However, TLRs can activate NF-κB transcription factors in response to nonmicrobial endogenous ligands, namely damage-associated molecular patterns, in addition to microbial pathogens[10]. This activation has been implicated in noninfectious inflammatory conditions such as diabetes[13,14] (Figure 1). TLRs are expressed in various extrinsic and intrinsic cell types in the kidneys including lymphocytes, macrophages, and endothelial and tubular epithelial cells[15]. The activation of renal TLRs, mainly TLR2 and TLR4, has been involved in the development of renal inflammation, leukocyte infiltration, and progressive fibrosis in various acute and CKD diseases, including DKD[16,17]. These observations have generated a new field of study focused on the development of new strategies that target TLR signaling with potential therapeutic utility in DKD.

TOLL-LIKE RECEPTORS IN DKD

Among TLRs, TLR2 and TLR4 have been particularly associated with the pathogenesis of renal ischemia-reperfusion injury, acute kidney injury, acute allograft rejection, and DKD[16,18,19]. Compelling evidence suggests that TLR2 and TLR4 are involved in the development of DKD through two pathways. On one hand, the upregulation of several pro-inflammatory endogenous ligands for TLR2 and TLR4 under diabetic conditions is a result of high glucose, hypoxia and hyperlipidemia[20,21]. On the other hand, the diabetic milieu increases TLR2 and TLR4 expression in monocytes, human kidney proximal tubular cells and endothelial cells[9,20,21]. The increased expression of TLRs in DKD amplifies the activation of the innate immune system in response to endogenous diabetes-related ligands, resulting in the development of sustained inflammation and fibrosis in the kidney, which are the hallmarks of DKD[22].
In both animal models and human studies, increased expression of TLR4 has been observed in diabetic kidneys[15]. Recent clinical studies suggest that TLR4, investigated by Wu et al[23], is the major TLR implicated in DKD[23]. Accordingly, kidney biopsies of DKD patients show increased expression of TLR4, but not TLR2, in the tubules[22]. Additionally, in DKD patients, TLR4 levels in renal glomeruli and tubules were found to have a positive correlation with HbA1c levels, albuminuria, interstitial macrophage infiltration, fibrosis, and tubular atrophy score, and a negative correlation with the glomerular filtration rate[20-22].

Experimental studies also suggest that TLR4 is involved in the pathogenesis of DKD. Renal TLR4 expression is increased in type 1 diabetes mouse models[24]. Nevertheless, TLR4 knock-out in these animals is associated with the amelioration of renal pathology and the reduction of diabetes-related TLR ligands and downstream markers of their activation[16,23,25,26]. Similarly, inhibiting TLR4 with drugs confers renoprotection to db/db and endothelial nitric oxide synthase knockout diabetes mouse models through different pathways, including metabolic and anti-glomerulosclerosis mechanisms, as well as the inhibition of NF-κB activation[26-29].

TARGETING TLRS: THE THERAPEUTIC POTENTIAL OF MICRORNAS

The understanding of the intricate relationship between DKD and TLR4 has provided potential therapeutic targets. Modulating TLR4 signaling offers a promising approach to address the underlying inflammation and delay the progression of DKD.

The study by Wu et al[23] in rats explores the therapeutic potential of microRNA-630 in mitigating inflammatory responses associated with DKD. MicroRNAs are short, non-coding RNA molecules, approximately 22 nucleotides in length. They play a pivotal role in regulating gene expression by targeting microRNAs for cleavage or translational repression after binding to the 3’-untranslated region[30]. The human genome contains more than 1000 microRNAs, and it is estimated that approximately 60% of human protein-coding genes may be regulated by microRNAs, suggesting their impact on the regulation of protein synthesis and thus on protein activity. Variations in microRNA expression have been linked to the development of various human diseases and there is increasing evidence pointing to their role in the development of DKD[31-33]. Accordingly, microRNA-302a-3p levels are inversely related to albuminuria in patients with DKD. In vitro experiments suggest its potential role in modulating the renal epithelial-mesenchymal transition process[32]. Conversely, microRNA-184 has been reported to contribute to albuminuria driving renal fibrosis in an experimental rat model of DKD[33]. In addition, microRNA-27a can promote podocyte injury by activating β-catenin in diabetic rats[34].

Wu et al[23], presented evidence of a protective effect of the microRNA-630 on DKD by targeting TLR4 and inhibiting the inflammatory reaction. The authors observed reduced levels of microRNA-630 in the renal tissue of rats with streptozotocin-induced DKD. Furthermore, DKD rats treated with microRNA-630 agomir experienced a significant reduction in albuminuria, glycermia, kidney expression levels of TLR4, and the proinflammatory markers tumor necrosis factor α (TNF-α), IL-1β, and IL-6 compared to non-treated rats. In addition, microRNA-630 agomir-injected DKD rats exhibited fewer kidney lesions and reduced infiltration of inflammatory cells. Wu et al[23] also determined the variations in microRNA-630 and TLR4 gene expression levels in the kidney epithelial-like cell line NRK-52E, cultured under high-glucose conditions. Their findings revealed a significant decrease in microRNA-630 levels and an increase in TLR4 and inflammatory TNF-α, IL-1β, and IL-6 expression. Similarly, high glucose conditions induced a significant decrease in the protein levels of TLR4, α-smooth muscle actin, and collagen IV in NRK-52E cells. Notably, the rise in TLR4, pro-inflam-
matory cytokines, E-cadherin, α-smooth muscle actin, and collagen IV, which is dependent on high glucose, was abolished when the cells were treated with a mimic of microRNA-630, indicating its relevant regulatory role.

In fact, similar results have recently been observed with microRNA-874 in DKD rats[31]. Consistent with the results obtained by Wu et al[23] with microRNA-630, overexpression of microRNA-874 was able to alleviate kidney injury. Moreover, microRNA-874 reversed the antiproliferative and apoptotic effects in a glucose-induced mouse podocyte model and dramatically attenuated the inflammatory response. Similarly, microRNA-874 was found to be able to reduce TLR4 levels in podocytes.

The evidence presented here suggests that targeting TLR4 and its downstream signaling pathways through microRNAs is a potential avenue for therapeutic intervention in DKD. Inhibitors or modulators of TLR4 signaling are being explored in preclinical and clinical studies as potential treatments to decrease inflammation and delay the progression of kidney disease in diabetic patients.

The study by Wu et al[23] has important implications for the development of novel therapeutic strategies for DKD. MicroRNA-630-based interventions could provide a targeted and precise approach to ameliorate inflammation in diabetic kidneys if the results can be translated to humans. This could potentially slow or even halt the progression of DKD and improve the quality of life for people living with this debilitating complication of diabetes.

**CHALLENGES AND CONSIDERATIONS**

As with any groundbreaking research, several challenges and considerations must be addressed. The transition from animal models to human trials is a crucial step that requires careful consideration. Ethical and safety considerations in the development of microRNA-based therapies for DKD include thorough evaluation of long-term safety and efficacy, monitoring for off-target effects, adherence to ethical principles in clinical research, ensuring equitable access and affordability, and compliance with regulatory standards for approval and commercialization. Responsible management of these issues will be critical to the advancement of future microRNA-based therapies for DKD.

**SUMMARY**

The studies on microRNA-630 and its role in alleviating inflammatory responses in rats with DKD offer hope in the field of diabetes-related complications. The potential therapeutic implications of this research are significant and open the door to broader clinical applications, although much work remains to be done. Targeted interventions such as microRNA-630 hold significant promise not only for DKD but also for the treatment of other inflammatory conditions associated with diabetes. In addition, understanding the molecular mechanisms underlying the effects of microRNA-630 may lead to the development of novel therapeutic strategies targeting similar pathways.

Looking ahead, future research in this area could take several directions. First, clinical trials are needed to validate the efficacy and safety of microRNA-630-based interventions in patients with DKD. Longitudinal studies following patients over time would provide valuable insights into the durability of treatment effects and potential long-term benefits. In addition, investigating the interplay between microRNA-630 and other molecular pathways involved in DKD may reveal synergistic therapeutic approaches or identify biomarkers for patient stratification. Moreover, off-target effects of microRNA-630 derived from the disruption of normal immune function cloud potentially include an increased susceptibility and recurrence of infections and even reactivation of latent ones.

Furthermore, exploring the potential of microRNA-630 as a diagnostic or prognostic marker for DKD may improve early detection and risk stratification, allowing timely intervention to prevent or slow disease progression. Finally, the evident complexity of DKD demands essential interdisciplinary collaborations integrating expertise from genetics, molecular biology and clinical medicine to advance our understanding of the disease and translate research findings into effective clinical interventions.

**CONCLUSION**

The study by Wu et al[23] on the role of microRNA-630 in diabetes is an important milestone but also provides a catalyst for further exploration and innovation in diabetes research. As we further dissect the molecular mechanisms of DKD and continue to develop targeted interventions, we can work toward a future where the burden of diabetes-related renal complications is substantially reduced, improving the lives of patients worldwide.

**FOOTNOTES**

**Author contributions:** Donate-Correa J, González-Luis A, Díaz-Vera J and Hernandez-Fernaud JR designed this editorial; González-Luis A, Díaz-Vera J and Hernandez-Fernaud JR contributed to the data collection and editing of the manuscript; Donate-Correa J wrote the paper; All the authors have read and approved the final version of the present manuscript.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.
REFERENCES


Donate-Correa J et al. MicroRNA-630 and diabetic kidney disease


